Elena Castro, MD, PhD

Formal discussant of the TRITON3 trial, Elena Castro, MD, PhD, of the Hospital Universitario 12 de Octubre, Madrid, noted that the study helps to answer several questions raised by the PROfound trial.

In the PROfound trial, a cohort of patients with at least one alteration in BRCA1, BRCA2, or ATM treated with the PARP inhibitor olaparib had an imaging-based progression-free survival and overall survival that was significantly longer than that for the group treated with physician’s choice of enzalutamide or abiraterone.

Dr. Castro pointed out that most of the benefit in PROfound was driven by patients with BRCA2 mutations, noting that it was unclear in that trial and TRITON3 whether patients with ATM alterations derive any benefit from PARP inhibition. She also said that TRITON3 is the first study to show data on how PARP inhibitors compare with a taxane (docetaxel) in metastatic castration-resistant prostate cancer. 

DISCLOSURE: Dr. Castro reported financial relationships with Astellas Pharma, AstraZeneca, Bayer, Clovis Oncology, Janssen-Cilag, Pfizer, Roche, Merck, MSD Oncology, Novartis, and SYNLAB.